What Guidance are Economists Given on How to Present Economic Evaluations for Policymakers? A Systematic Review  by Sullivan, Shannon M. et al.
Avai lable onl ine at www.sc iencedirect .comV A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 9 1 5 – 9 2 41098-3015$36.00 – s
Published by Elsevie
http://dx.doi.org/10
E-mail: ssull011@
* Address corresp
Canada K1Y 4W7.journal homepage: www.elsevier .com/ locate / jva lSYSTEMATIC REVIEWSWhat Guidance are Economists Given on How to Present
Economic Evaluations for Policymakers? A Systematic Review
Shannon M. Sullivan, PhD1,*, George Wells, PhD1,2, Doug Coyle, PhD2
1University of Ottawa Heart Institute, Ottawa, ON, Canada; 2School of Epidemiology, Public Health and Preventive Medicine,
University of Ottawa, Ottawa, ON, CanadaA B S T R A C TObjectives: To systematically review health economic guidelines for
information on how to present health economic evaluations and
consider implications for nontechnical audiences such as policy-
makers. Methods: Electronic databases and supplementary sources
were searched for economic evaluation guidelines. Guidelines were
critically appraised. Descriptive characteristics, standard formats,
supports for nontechnical audiences, presentation approaches, and
common reporting recommendations were extracted. Frequencies
were tabulated and trends identiﬁed. Results: Thirty-one guidelines
were included. Twenty-two guidelines include a standard reporting
format with some sample tables and graphs. Common presentation
approaches include well-cited tables of data sources, transparent
model diagrams and descriptions, disaggregated results, and tabular
and graphical displays of sensitivity analyses. Despite most guidelines
being funded by policymakers, only ﬁve guidelines provided advice on
presenting economic evaluations to noneconomists. However, 11
guidelines included a glossary of economic terminology for non-
technical readers. Common concepts that may require furtheree front matter Copyright & 2015, International S
r Inc.
.1016/j.jval.2015.06.007
uottawa.ca.
ondence to: Shannon M. Sullivan, PhD, Universityexplanation include differences in economic perspectives, appropri-
ateness of time horizons, how economic outcomes such as quality-
adjusted life-years relate to their component clinical outcomes, and
choice of sensitivity analyses. Conclusions: Health economists have
consistent presentation formats and common reporting elements that
should be considered when developing user-friendly explanations for
general audiences. These overlap with policymakers’ informational
needs but may not be sufﬁcient for understanding by nontechnical
audiences. Developing presentation formats and tools that incorpo-
rate viewpoints of both economists and noneconomists will allow for
better application of the results of economic evaluations and enhance
the transparency and legitimacy of decision-making processes that
are informed by economic evaluations.
Keywords: economic evaluation, guidelines, presentation formats,
systematic review.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Using cost-effectiveness analyses in health policy and reimburse-
ment decisions has sometimes been questioned, and the policy
impact of health economic evaluations is still uncertain after 20 years
[1,2]. Enhancing the transparency and understanding of economic
evaluations could increase conﬁdence in and perceived legitimacy of
health technology assessment decision-making processes [3,4].
Economic evaluations are not always provided in an accessible
format, and more effective presentation of economic evaluations
could increase understanding of how economic evaluations inform
policy decisions. This would also enable policymakers to better
defend decisions that are based, in part, on economic evaluations.
Health policy decision makers, and those affected by policy
decisions such as the tax-paying public, patients, and health care
providers, generally do not have the same technical expertise ashealth economists [5]. However, they are important end users of
economic evaluations. Policymakers sometimes have limited
training in health economics and may be unclear in how to
practically apply the results of economic evaluations to actual
decisions if results are not clearly presented [6,7].
Providing simple but robust explanations of economic evalua-
tions to a nontechnical audience is challenging [8]. An appropriate
balance of making information understandable while maintaining
the completeness and technical accuracy of the economic evalua-
tion must be achieved. Oversimplifying technical information may
lose important nuances that are relevant for practical and con-
sistent decision making. Therefore, considering how economists
present their work to policymakers and other lay audiences merits
further exploration. A number of studies have reported on policy-
makers’ use of economic evaluations. In general, policymakers
want to be able to deconstruct analyses, identify key principles,ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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[9–11]. It is unclear how this aligns with what economists consider
important to present in economic evaluations.
Elements that economists report on are described in guide-
lines for conducting economic evaluations [12,13]. The general
purpose of these guidelines is to increase both the methodological
quality of economic evaluations and the transparency of how
they are conducted. Although good reporting practices outlined in
health economic guidelines are important to follow and can
contribute to clarity, they may be insufﬁcient for good communi-
cation to nontechnical audiences [5,14]. Although adequately
reporting economic modeling details is a ﬁrst essential step that
provides a transparent description of the analysis and results to
the reader, subsequently arranging this information in presenta-
tion formats that assist end users in their understanding and/or
application of the information is also an important consideration.
Developing tools and alternate presentation formats that enhance
the accessibility of economic evaluations may be one approach to
increasing their impact and value to clinicians and policymakers.
Although standards for transparent health economic reporting
may be consistent, regardless of the audience or topic, different
presentation formats may be appropriate for different audiences
or topics. It is unclear how much guidance economists are given
with respect to presentation formats and tailoring presentation of
their work to noneconomists such as policymakers.
A systematic approach to knowledge translation [15] and the
development of economic tools that would enhance accessibility
of health economics and conﬁdence in health policy decision
making would be of value. Incorporating guidance from economic
guidelines on reporting and presentation standards would lead to
knowledge translation tools that can robustly represent complex
economic information.
The objective of this study was to systematically review
guidelines to determine what guidance economists are provided
on how to present economic evaluations and whether any of this
guidance is targeted toward nontechnical end users such as
policymakers. Our primary hypothesis was that guidance pro-
vided to health economists on presenting economic evaluations
is not focused on the needs of nontechnical end users of
economic evaluations. We also hypothesized that some elements
commonly required for transparent reporting are technical con-
cepts that may require further explanation for nontechnical
audiences. Although economic guidelines are developed for
multiple audiences including economists in academic settings,
industry, or research organizations, our ﬁndings will be inter-
preted in the context of nontechnical audiences who apply the
results of economic evaluations to policy decisions.Methods
Systematic Review Protocol
A systematic review was conducted following Cochrane method-
ology [16]. Guidelines for conducting and/or reporting on eco-
nomic evaluations of pharmaceuticals were included that
primarily targeted economists and researchers who were provid-
ing economic evaluations for policymakers and other end users.
Guidelines for assessing the quality of economic evaluations
were excluded because they primarily target end users of eco-
nomic evaluations and not economists who produce economic
evaluations. Guidelines were excluded if they addressed only
speciﬁc components of economic evaluations (e.g., modeling and
willingness to pay) and not economic evaluations as a whole; if
they addressed affordability (i.e., budget impact) rather than cost
effectiveness; or if they advocated a disease-speciﬁc or
technology-speciﬁc (e.g., diagnostic tests and medical devices)approach to economic evaluation. Editorials or opinion articles
providing recommendations with no supporting evidence base or
methodological process for developing the recommendations were
excluded. Guidelines were also excluded if they were not directly
linked to a decision-making or reimbursement process; this crite-
rion limited the review to those guidelines most likely to provide
approaches to presenting economic evaluations to nontechnical
audiences such as policymakers. Finally, if more recent versions of
the guidelines were available or if the guideline was developed
before 2000, guidelines were excluded. The latter criterion was
necessary given the methodological advances in the discipline. No
language restrictions were applied. Outcomes of interest were the
type and frequency of information on presentation formats and
the type and frequency of key reporting recommendations.
Search Strategy
Databases searched included Medline (1996 to November 2013),
EMBASE (1980 to November 2013), and the Cochrane Database of
Systematic Reviews, using a date limit of 2000 but no language
restriction. The search terms were “guidelines,” “health economics,”
and “economic evaluation.” The gray literature was searched for
unpublished studies using the Canadian Agency for Drugs and
Technologies in Health Gray Matters checklist as a guide, in
addition to other relevant economic and guideline resources,
including Web sites for the International Society for Pharmacoe-
conomics and Outcomes Research (ISPOR), the Enhancing the
QUAlity and Transparency Of health Research network, and the
Guidelines International Network [17–20]. Studies were also
selected through hand searching of selected journals, reviewing
reference lists of potentially relevant studies, and suggestions
from economic experts.
Study Selection
Citations were screened for relevance by one review author on
the basis of the title and abstract of identiﬁed articles. Two review
authors independently reviewed the full text of potentially
relevant guidelines to assess exclusion or inclusion.
Critical Appraisal
Guideline quality was assessed using items identiﬁed in the
Appraisal of Guidelines for Research & Evaluation (AGREE) II
instrument [21]. The AGREE II instrument was designed to assess
clinical practice guidelines and has six domains: scope and
purpose, stakeholder involvement, rigor of development, clarity
of presentation, applicability, and editorial independence. The
overall purpose of the AGREE II instrument is “to provide a
framework to: assess the quality of guidelines; provide a meth-
odological strategy for the development of guidelines; and inform
what information and how information ought to be reported in
guidelines” [21]. No instruments, however, currently exist to
speciﬁcally assess either the quality of methodological guidelines
or guidelines for economic evaluations. Therefore, minor mod-
iﬁcations to items in the AGREE II instrument were made to apply
the instrument to economic guidelines. Principles from a frame-
work for communicating conﬁdence in methodological recom-
mendations for systematic reviews and meta-analyses were also
incorporated into the assessment (for more details, see Appendix
Table 1 in Supplemental Materials found at http://dx.doi.org/10.
1016/j.jval.2015.06.007) [22]. These principles included consider-
ation of different sources of evidence and approaches and criteria
for selecting evidence that may differ in methodological guide-
lines. Because of these modiﬁcations, we did not feel it was
appropriate to apply the standard AGREE II scoring system but
used items in the instrument as a guide to identify potential
limitations.
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The following data were extracted from guidelines (for detailed
deﬁnitions of variables, see Table 2 in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2015.06.007).1. Descriptive characteristics: geographic location, publication
year, author afﬁliations, guideline purpose, type of guideline,
target audience.2. Standard templates: whether a standard reporting template,
sample tables, or sample ﬁgures were provided,3. Supports for nontechnical end users: if a glossary was pro-
vided, whether advice was provided on presenting to
noneconomists.4. Presentation formats and approaches: details on how to
present data sources, model, base-case results, and sensitivity
analyses (deterministic and probabilistic). These four areas
were selected as key components of an economic evaluation,
and data extraction focused on the format for presenting the
information, not just that the information be provided or
reported (i.e., focusing on “how” to report not just “what” to
report).5. Recommendations for the conduct and transparent reporting
of economic evaluations: perspective, target population, sub-
group analyses, time horizon, assumptions required, model-
ing, preferred outcome measures, sensitivity analysis
parameters, sensitivity analysis ranges, and methods for
conducting sensitivity analyses. These elements were
selected from variables in the ISPOR database [18,23].
Although some of these elements relate to the methodology
and conduct of economic evaluations, they were included
because they may inﬂuence the overall approach to present-
ing economic evaluations to nontechnical audiences.
Detailed guidance on how to conduct an economic evaluation
was not extracted (e.g., analytic approaches and distributions to
apply) and is not the focus of this systematic review. When
available, guideline characteristics from the ISPOR database
[18,23] were used, and were veriﬁed with source documents by
one author. A second author veriﬁed disagreements. For all
remaining data, including the guideline critical appraisal, one
author extracted data, which were veriﬁed by a second author. A
third reviewer resolved disagreements.Data Analysis
The frequency of recommendations on reporting and presenting
economic evaluations was tabulated and common trends were
noted. More speciﬁcally, trends were considered on the basis of
year of publication, geographic location, and critical appraisal
domains (e.g., stakeholder involvement in guideline
development).Results
Of the 6099 citations identiﬁed, 32 reports, representing 31
guidelines, were included (see Appendix Figure in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2015.06.007)
[13,24–54]. Approximately half were country-speciﬁc pharmacoe-
conomic evaluation guidelines recognized by decision-making
bodies (54%, n ¼ 17 of 31), 22% (n ¼ 7 of 31) were submission
guidelines identifying requirements for economic evaluations
submitted to decision-making bodies, and 22% (n ¼ 7 of 31) were
published recommendations on economic evaluations. Descrip-
tive characteristics of the guidelines are described in Table 1,
with additional details provided in Appendix Table 3 inSupplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2015.06.007.
Critical Appraisal of Guidelines
Guideline quality was generally low when critically appraised. All
guidelines had some limitations related to the rigor of their
development and editorial independence. Guidelines varied with
respect to the degree of stakeholder involvement and their focus
on applicability and implementation. Guidelines from Brazil and
Cuba, however, were well developed in both these domains.
Common limitations were not conducting a systematic search
for evidence and an unclear process for formulating recommen-
dations. Although recommendations were clearly identiﬁed in
most guidelines, differences in terminology when comparing
across guidelines could create confusion and lead to lack of
clarity. Decision makers and related organizations frequently
provided funding for the guidelines; however, authors’ potential
conﬂicts of interest were not reported in most of the guidelines.
More details on the critical appraisal are provided in Appendix
Table 4 in Supplemental Materials found at http://dx.doi.org/10.
1016/j.jval.2015.06.007.
Standard Templates: Reporting Templates, Sample Figures,
and Sample Tables
Most of the guidelines (71%, n ¼ 22 of 31) provided a standard
reporting format for an economic evaluation. The speciﬁc content
of the report format varied across guidelines but generally
addressed major components of the analysis including the
design, methods, evidence summary, results, and interpretation.
Some guidelines provided sample tables (32%, n ¼ 10 of 31) and
ﬁgures (16%, n ¼ 5 of 31) for presenting economic evaluations.
When all the guidelines were reviewed in detail, however, each
provided some guidance on presenting various elements of
economic evaluations and is included in the subsequent syn-
thesis on how to present economic evaluations. Formal methods
for assessing and designing the reporting structure, format, and
content of economic evaluations were not identiﬁed in any of the
guidelines, and none of the reporting templates speciﬁcally
targeted policymakers or other nontechnical audiences.
Supports for Nontechnical End Users: Glossaries and Advice
on Presenting to Noneconomists
Guidelines were most frequently developed by or in collaboration
with policymakers (87%, n ¼ 27 of 31) and targeted toward
industry (90%, n ¼ 28 of 31), policymakers (90%, n ¼ 28 of 31),
or researchers (77%, n ¼ 24 of 31). Advice on presenting economic
evaluations to nontechnical audiences was noted in 16% of the
guidelines (n ¼ 5 of 31). The American guideline suggested that
model calculations should be clearly explained for nonecono-
mists and results disaggregated for formulary committees [34].
The Thai guideline suggested that graphical presentations of
results would assist general audiences [44]. Three guidelines
(Brazil, Mexico, and Canada) recommended including an execu-
tive summary accessible to noneconomists [13,38,43] (for more
details, see Appendix Table 5 in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2015.06.007). In addition, 35% of
the guidelines (n ¼ 11 of 31) included a glossary of technical
terms for those less familiar with health economics. No trends
across geographic region or year of publication were identiﬁed for
guidelines that included advice on presenting to noneconomists
or that included a glossary. Four of the 5 guidelines that provided
advice on presenting to noneconomists and 10 of the 11 guide-
lines with glossaries, however, were developed with good stake-
holder involvement.
Table 1 – Characteristics of economic evaluation guidelines.
Country Author
afﬁliation
Target audience Standard
reporting
format
Sample
tables
included
Sample
ﬁgures
included
Glossary
included
Presenting to
noneconomists
Pharmacoeconomic guidelines*
Columbia 2014 Decision makers,
researchers
Industry, decision
makers,
researchers
Yes Yes – – –
South Korea
2013
Decision makers Industry, decision
makers,
researchers
– Yes Yes Yes –
Norway 2012 Decision makers Industry, decision
makers,
researchers
No – – – –
Ireland 2010 Decision makers Industry, decision
makers,
researchers
– Yes Yes Yes –
Brazil 2009 Decision makers,
researchers
Industry, decision
makers,
researchers
Yes – – Yes Yes
Germany 2009 Decision makers Decision makers – – Yes Yes –
Belgium 2008 Decision makers Industry, decision
makers,
researchers
Yes Yes – – –
Mexico 2008 Researchers,
decision
makers
Industry, decision
makers,
researchers
Yes – – Yes Yes
Slovakia 2008 Decision makers,
researchers
Industry, decision
makers,
researchers
Yes – – – –
New Zealand
2007
Decision makers Industry, decision
makers,
researchers
Yes Yes – Yes –
Canada 2006 Decision makers Decision makers Yes – Yes Yes Yes
Taiwan 2006 Researchers,
industry
Industry, decision
makers,
researchers
Yes – – – –
The
Netherlands
2006
Decision makers,
researchers
Industry, decision
makers,
researchers
Yes – – – –
Cuba 2003 Decision makers,
researchers
Industry, decision
makers,
researchers
Yes – – Yes –
France 2003 Researchers Industry, decision
makers,
researchers
Yes – – – –
Sweden 2003 Decision makers Industry, decision
makers
– – – – –
Baltic States
2002
Decision makers Industry, decision
makers
– – – – –
Submission guidelines*
England &
Wales 2013
Decision makers Industry,
researchers
– – – Yes –
Israel 2010 Decision makers Industry, decision
makers,
researchers
Yes Yes – – –
Finland 2009 Decision makers Industry,
researchers
– – – – –
Australia 2008 Decision makers Industry Yes Yes – – –
Thailand 2008 Researchers,
decision
makers
Industry, decision
makers,
researchers
Yes – Yes – Yes
Scotland 2007 Decision makers Industry, decision
makers
– – – – –
continued on next page
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Table 1 – continued
Country Author
afﬁliation
Target audience Standard
reporting
format
Sample
tables
included
Sample
ﬁgures
included
Glossary
included
Presenting to
noneconomists
Poland 2007 Decision maker,
researchers
Industry, decision
makers,
researchers
Yes – – – –
Published pharmacoeconomic recommendations*
South Africa
2013
Decision makers Industry, decision
makers,
researchers
Yes – – – –
China 2011 Decision maker,
researchers
Industry, decision
makers,
researchers,
clinical providers
Yes – – Yes –
Russia 2010 Researchers Industry, decision
makers,
researchers
Yes Yes – – –
Spain 2009 Decision makers,
researchers
All: Industry,
decision makers,
researchers,
health providers,
patients, citizens
– – – – –
USA 2009 Decision maker Decision makers,
researchers
Yes Yes – Yes Yes
Hungary 2002 Decision maker,
researchers
Industry, decision
makers, health
providers
Yes – – – –
Italy 2001 Decision maker,
researchers,
industry
Industry, decision
makers,
researchers
Yes – – – –
ISPOR, International Society for Pharmacoeconomics and Outcomes Research.
* As deﬁned in the ISPOR guideline database [18,20], guidelines were categorized as Pharmacoeconomic Guidelines (country-speciﬁc “ofﬁcial”
guidelines or policies concerning economic evaluation that are recognized or required by the health care decision-making bodies/entities in
this country/region for reimbursement), Submission Guidelines (country-speciﬁc “ofﬁcial” guidelines or policies concerning drug submission
requirements with an economic evaluation part/section and are required by the health care decision-making bodies/entities in this country/
region for reimbursement), or Published Pharmacoeconomic Recommendations (country-speciﬁc economic evaluation guidelines or
recommendations published by experts in the ﬁeld but are not “ofﬁcially” recognized or required by the health care decision-making
bodies/entities in this country/region for reimbursement).
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Recommendations on how to present economic evaluations that
appeared in at least 20% of the guidelines are provided in Table 2.Presenting data sources
Sixty-eight percent (n ¼ 21 of 31) of the guidelines provided
direction on how to present data sources.
The most common suggestions for presentation approaches
were providing appropriate cross-referencing and citations of
sources (48%, n ¼ 15 of 31) and providing detailed tables or a list
of included variables and data (39%, n ¼ 12 of 31). Guidance on
which variables to include in the tables varied, with some
requesting all variables, others requesting only the most impor-
tant variables, and some indicating only that there should be
sufﬁcient transparency to reproduce the analysis. Presenting a
list or table including resource use and costs was also sometimes
recommended (26%, n ¼ 8 of 31).
Less frequently recommended approaches for presenting data
sources included having copies of original data sources or ensuring
their availability (13%, n ¼ 4 of 31), summarizing clinical trial data
in tables (10%, n ¼ 3 of 31), and including a quality assessment of
the data sources (6%, n ¼ 2 of 31). Three guidelines (10%, n ¼ 3 of31) also suggested providing more detailed information such as
data collection forms or detailed data tables in appendices.Presenting economic models
Sixty-eight percent (n ¼ 21 of 31) of the guidelines provided
suggestions on presenting the economic model. Many guidelines
(39%, n ¼ 12 of 31) emphasized the need for transparency and
clarity in presenting the model description so that the analysis
could be replicated and individuals can understand the justiﬁca-
tions or why it is different from other existing models. It was
noted that the presentation should allow individuals to follow
the steps in the modeling and analysis and understand how the
data move through the model. Similarly, a number of guidelines
emphasized the need for clarity in presenting model assump-
tions (32%, n ¼ 10 of 31). Figures commonly suggested included
decision tree diagrams (29%, n ¼ 9 of 31) or model structure
diagrams (29%, n ¼ 9 of 31). For the model structure diagrams,
guidelines either requested traditional transition-state Markov
model diagrams or did not specify details of the model diagram.
Only one guideline speciﬁed that a less-detailed schematic
diagram of the model be provided for noneconomists [34].
Presenting transition probabilities in a matrix was less frequently
recommended (10%, n ¼ 3 of 31).
Table 2 – Presentation approaches recommended in
at least 20% of the economic guidelines.
Recommendations on how to present
information
Guidelines
(N ¼ 31),
n (%)
Data sources
Cross-referencing and citations of sources 15 (48)
Detailed table of data and variables 12 (39)
Table of resource use and costs 8 (26)
Model
Model description transparent enough to
justify and/or replicate
12 (39)
Assumptions and/or methods clearly
presented
10 (32)
Decision tree diagram 9 (29)
Relevant model diagram and structure
presented
9 (29)
Base-case results
Disaggregated results to increasingly
aggregated
19 (61)
Incremental costs and beneﬁts presented 19 (61)
Total costs and beneﬁts presented 15 (48)
Tables of results 12 (39)
Graphical displays requested or encouraged 7 (23)
Sensitivity analyses
Deterministic
Tabular format 9 (29)
Tornado diagrams to highlight drivers 8 (26)
Identify inﬂuential parameters affecting
results
8 (26)
Probabilistic
Cost-effectiveness acceptability curve 11 (35)
Scatter plot—cost-effectiveness plane 10 (32)
Note. Multiple recommendations could be made in each guideline.
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Ninety-four percent (n ¼ 29 of 31) of the guidelines provided
suggestions on how to present the base-case results. Although
presenting incremental changes in results was predominantly
recommended (61%, n ¼ 19 of 31), many guidelines recom-
mended that total costs and beneﬁts also be presented (48%,
n ¼ 15 of 31) to aid in the interpretation of results. Some
guidelines also speciﬁcally requested that uncertainty around
the incremental cost-effectiveness ratio be presented using
either conﬁdence intervals or a range for the incremental
cost-effectiveness ratio (13%, n ¼ 4 of 31). Some guidelines
(10%, n ¼ 3 of 31) recommend presenting results using natural
clinical units before converting to quality-adjusted life-years
(QALYs) (e.g., heart attacks, cirrhosis, and adverse events
avoided). Some guidelines (10%, n ¼ 3 of 31) also suggested
presenting costs and beneﬁts at a per-patient level, not just a
population level.
Many guidelines recommended reporting results in disaggre-
gate as much as possible, leading up to aggregate responses (61%,
n ¼ 19 of 31). Examples of disaggregating results included
presenting costs and effects separately for each intervention
and presenting results for different subpopulations, disease
states, model cycles, or health care settings. In addition, some
guidelines recommended separately reporting QALYs and life-
years when there was a survival beneﬁt (13%, n ¼ 4 of 31). Some
guidelines (13%, n ¼ 4 of 31) indicated that results should be
presented in a way to allow veriﬁcation or reproducibility. Two
guidelines (6%) also indicated that the limitations and/or quality
of the results should be described for transparency purposes.Presenting results in tables was frequently recommended
(39%, n ¼ 12 of 31). Speciﬁc suggestions for tables included
summarizing costs, effects, and cost- effectiveness for each
therapy or comparing short-term trial-based results with long-
term extrapolations. Presenting results using general graphical or
visual displays was encouraged (23%, n ¼ 7 of 31). Speciﬁc types
of graphics included the cost-effectiveness plane (13%, n ¼ 4 of
31), net beneﬁt (6%, n ¼ 2 of 31), changes in outcomes over time
when permitted by the model (3%, n ¼ 1 of 31), and willingness to
pay (3%, n ¼ 1 of 31).
Some guidelines also recommended discussing practical
issues when presenting results. For example, presenting results
that allow one to determine relevance or generalizability to the
population was recommended in two guidelines (6%). This could
include consideration of disease epidemiology, population char-
acteristics, practice patterns, or patterns of resource use. One
guideline (3%) also requested that the magnitude and direction of
this impact also be clearly identiﬁed. Some guidelines (13%, n ¼ 3
of 31) requested presentation of cost saving and/or opportunity
costs when relevant. Additional suggestions related to the rele-
vance and applicability of results included noting implementa-
tion factors and the feasibility of adopting on the basis of
ﬁnancial constraints (3%, n ¼ 1 of 31) or the ability to reallocate
freed resources for other purposes (3%, n ¼ 1 of 31). Two guide-
lines (6%) provided suggestions on how to present conclusions,
including suggestions for standard wording when presenting
cost-effectiveness results [42,47].
Presenting deterministic sensitivity analyses
Sixty-one percent (n ¼ 19 of 31) of the guidelines provided
suggestions on how to present the deterministic sensitivity
analyses results. A summary of the parameters that should be
subjected to sensitivity analyses is described later, in Table 3, as
part of guideline reporting requirements.
The most common recommendation was presenting sensitiv-
ity analyses in tables (29%, n ¼ 9 of 31). Speciﬁc types of tables
included a table comparing sensitivity analyses of broader drug
use with the intended drug use, a matrix of variable effects and
outcomes that differ between two comparators, and tabulating
the sensitivity analyses beside the base-case results. Presenting
sensitivity analyses using tornado diagrams to highlight key
drivers (26%, n ¼ 8 of 31) and identifying inﬂuential parameters
that have an impact on results (26%, n ¼ 8 of 31) were also
frequently recommended.
Presenting probabilistic sensitivity analyses
Forty-two percent (n ¼ 13 of 31) of the guidelines provided
suggestions on how to present probabilistic sensitivity analyses.
The most frequently recommended formats were the cost-
effectiveness acceptability curve (35%, n ¼ 11 of 31) and the
scatter plot for the cost-effectiveness plane (32%, n ¼ 10 of 31).
Less frequent recommendations included presenting in a tabular
format (10%, n ¼ 3 of 31), presenting expected value of informa-
tion analyses (3%, n ¼ 1 of 31), and identifying the percentage of
simulations that are cost saving (3%, n ¼ 1 of 31).
Recommendations for Conducting and Transparently
Reporting Economic Evaluations
Recommendations for conducting and transparently reporting
economic evaluations that appeared in at least 20% of the
guidelines are provided in Table 3. Less frequent recommenda-
tions are outlined in Appendix Table 6 in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2015.06.007.
The perspectives most frequently recommended were that of
the health care payer and the societal. Some guidelines suggested
Table 3 – Approaches for conducting and transpar-
ently reporting economic evaluations recom-
mended in at least 20% of the guidelines.
Guideline
element
Recommendations on
conduct and reporting
Guidelines
(N ¼ 31),
n (%)
Primary
perspective
Health care payer 19 (61)
Societal 14 (45)
Target
population
Approved indication 19 (61)
Clearly speciﬁed target
population
13 (42)
Subgroup
analyses
Requested/permitted but
no speciﬁc guidance
20 (65)
Time horizon Long enough to cover
consequences and
beneﬁts
19 (61)
Disease characteristics
considered
8 (26)
Assumptions
required
Yes 21 (68)
Modeling
permitted
Yes, requires details 12 (39)
Yes, details not speciﬁed 7 (23)
Preferred
outcome
measures
Quality-adjusted life-years 26 (84)
Natural, clinically relevant
or patient-relevant units
22 (71)
Life-year gained or
mortality
20 (65)
Quality of life 11 (35)
Sensitivity
analyses—
Parameters
Parameters with greatest
uncertainty
18 (58)
Sensitivity
analyses—
Range
Conﬁdence intervals 8 (26)
Representing full or
credible range of
variability
8 (26)
Extreme or best/worst-case
values
7 (23)
Sensitivity
analyses—
Methods
One-way or univariate 21 (68)
Multiway or multivariate
scenario analyses
17 (55)
Probabilistic 16 (52)
Note. Multiple recommendations could be made in each guideline.
For more details, see ISPOR Guideline Tables [18] and Appendix
Table 6 in Supplemental Materials.
ISPOR, International Society for Pharmacoeconomics and Out-
comes Research.
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though one perspective was recommended as the base case,
other perspectives were identiﬁed as optional.
The approved indication (61%, n ¼ 19 of 31) or a clearly
speciﬁed target population (42%, n ¼ 13 of 31) was the most
frequently recommended population. Subgroup analyses were
requested or permitted (65%, n ¼ 20 of 31), but common guidance
across guidelines on which subgroups should be analyzed was
not provided.
Use of a time horizon that could account for all the outcomes
and consequences was most frequently recommended (61%, n ¼
19 of 31). Considering the disease characteristics when selecting
the time horizon was also frequently recommended; for example,
natural history, chronic versus acute, and long-term effects (26%,
n ¼ 8 of 31).
Assumptions were permitted in most guidelines (68%, n ¼ 21
of 31), and modeling details were also required (61%, n ¼ 19 of 31).Common guidance was not provided for either aspect except to
indicate that choices should be justiﬁed and transparently
described.
Outcome measures most frequently preferred were QALYs
(84%, n ¼ 26 of 31); natural clinical measures (71%, n ¼ 22 of 31;
e.g., adverse events avoided and heart attacks) that could be
converted to QALYs, life-years, or mortality (65%, n ¼ 20 of 31);
and quality of life (35%, n ¼ 11 of 31).
The most frequent methods of conducting sensitivity analy-
ses were one-way (68%, n ¼ 21 of 31), multiway (55%, n ¼ 17 of
31), and probabilistic (52%, n ¼ 16 of 31). Uncertain parameters
were most frequently explored in sensitivity analyses (58%, n ¼
18 of 31). The parameter values used in sensitivity analyses were
most frequently based on conﬁdence intervals (26%, n ¼ 8 of 31),
extreme best-case and worst-case scenarios (23%, n ¼ 7 of 31),
and those representing a full or credible range of variability (26%,
n ¼ 8 of 31).Discussion
Key Findings
Most guidelines offer some advice on how to present economic
evaluations, and many include a standard reporting format with
examples of tables and graphs to be included. None of the
reporting templates used formal methods for their design or
assessment, and none of the reporting templates speciﬁcally
targeted policymakers or nontechnical audiences. Common ideas
across guidelines include presenting well-cited tables of data
sources, transparent model descriptions and diagrams, disaggre-
gated results, and tabular and graphical displays of sensitivity
analyses. However, despite most guidelines being funded by
policymakers for the purpose of developing economic evalua-
tions for policymakers, only ﬁve guidelines provided speciﬁcs on
how to present economic evaluations to noneconomists. Some
guidelines included a glossary of economic terminology for non-
technical readers. Those guidelines that provided advice for
presenting to noneconomists or that included glossaries were
more likely to have good stakeholder involvement in their
development. Common elements that are required for trans-
parent reporting of economic evaluations and that may require
further explanation for noneconomists include differences
between the societal and health care payer perspectives,
adequacy of time horizons that cover the period of costs and
effects while appropriately considering aspects of the disease,
how economic outcomes such as QALYs and life-years relate to
their component clinical outcomes such as heart attacks or
adverse events, and how sensitivity analyses (methods, param-
eters, ranges) are chosen to be conducted. Best practices and
educational resources for communicating these concepts to non-
technical audiences could be further explored.Comparison with Other Literature
When considering whether this guidance is sufﬁcient for pre-
senting economic evaluations to nontechnical audiences, these
ﬁndings should be considered in light of 1) what policymakers
want from economic evaluations, and 2) frequent limitations in
economic models. Finding common ground between how econ-
omists present economic evaluations and what policymakers
need to understand from an economic evaluation is essential
for creating economic evaluations that adequately balance both
rigor and accessibility for those who must understand their
implications for real-world decisions. A recent ISPOR task force
partially attempted to address this gap by developing a
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credibility of economic modeling studies [55].
The recommendations for presentation formats and reporting
elements identiﬁed in these 31 guidelines sometimes overlap
with issues raised by policymakers when applying the results of
economic evaluations to policy decisions. Some similarities
include ensuring transparency of methods and disaggregation
of results. For example, policymakers have indicated that being
able to deconstruct the economic analysis [9] and clearly out-
lining model assumptions that contribute to an incremental cost-
effectiveness ratio [10] can facilitate their understanding. How-
ever, policymakers have also focused on understanding the
relevance of economic evaluation results to practical decisions
and implementation issues. For example, being aware of oppor-
tunity costs and appreciating the difference between theoretical
versus real-world cost saving are important considerations for
policymakers. However, only a few guidelines emphasized the
importance of presenting the cost saving or other factors related
to implementation and adoption feasibility. Even when speciﬁc
suggestions were provided on how to present information to
target audiences, these centered on enhancing clarity and trans-
parency, not on identifying relationships to real-world decisions.
Across guidelines, there were no common recommendations
on details to include when reporting on modeling and assump-
tions. However, these are important concepts when understand-
ing the limitations of economic evaluations. Common limitations
identiﬁed in submissions of economic evaluations for reimburse-
ment include uncertainty in clinical estimates or ﬂaws in con-
structing the economic model [56–58]. Ensuring that sufﬁcient
detail regarding the methods is provided to allow for consistent
decision making but doing so without overwhelming nontechni-
cal users requires some consideration. Some guidelines recom-
mended presenting more detailed tables or technical information
on modeling in appendices, which could help audiences focus on
the most relevant information in the reports. Given established
practices in economic evaluations, greater consistency across
economic guidelines than what was observed in our present
analysis would be desirable. Although consensus documents
such as the Consolidated Health Economic Evaluation Reporting
Standards statement did not meet the inclusion criteria for our
systematic review [12], initiatives such as this could offer con-
sistency and a potential structure for guiding the translation of
economic evaluations for less technically oriented audiences.
Strengths and Limitations
This is the ﬁrst work to systematically review the guidance
economists are given on how to present economic evaluations
and consider this in the context of policymakers and other
nontechnical audiences. The consistency of recommendations
across 31 guidelines suggests that key concepts were captured in
this systematic review. Guidelines were focused on the conduct
of health economic evaluations; however, other supportive docu-
ments or resources may exist in various countries or through
international collaborations (e.g., European network for Health
Technology Assessment) that provide insights on presenting eco-
nomic evaluations to nontechnical audiences. However, guidelines
are tools that are frequently accessed by economists. To manage
the scope of the review, we limited our review to guidelines that
are directly linked to decision-making and/or drug reimbursement
processes, for which it may be reasonable that presentation
approaches targeting noneconomists were addressed.
Methodological guidelines to critically appraise the quality of
economic evaluations do not exist, and a tool for critically
appraising clinical practice guidelines was adapted. Therefore,
concepts unique to methodological guidelines may have been
missed. To supplement the AGREE II approach to assessingclinical practice guidelines, principles from a framework for
communicating methodological recommendations for systematic
reviews and meta-analyses were incorporated [22]. This included
allowing for different sources of supporting evidence in guide-
lines (e.g., simulation studies and methodological case studies)
and considering the context in which the guidelines would be
applied (e.g., setting, target audience, and outcomes to be opti-
mized by the guidelines). Despite the limitations of adapting
these approaches to the current systematic review, the appraisal
allowed identiﬁcation of some key issues in the quality of the
guidelines. For example, few guidelines reported that a system-
atic search for evidence was conducted or identiﬁed a rationale
for the evidence upon which the guideline recommendations
were based. Without this level of transparency, it is unclear
whether or how guideline developers considered alternative
options when formulating recommendations. In addition, not
all guidelines reported authors’ afﬁliations and/or ﬁnancial or
intellectual conﬂicts of interest, which may have inﬂuenced
guideline recommendations. The quality of most guidelines was
low around these aspects and should be considered in future
if more efforts are devoted to enhancing guidelines on how
to present economic evaluations for different end users. Extract-
ing qualitative data from a wide variety of guideline documents
requires judgment. However, this task was facilitated by
the use of a pre-existing database of guideline characteristics
[18,23].
Policy Implications/Interpretation
Economists have consistent presentation formats and reporting
elements that should be considered when providing information
to policymakers. However, tailoring information to nonecono-
mists is also important to enhance the accessibility of economic
evaluations and their legitimacy in health policy decision mak-
ing. Although policymakers have inﬂuenced how economic
evaluations are conducted, less work has been done on how best
to present and communicate economic evaluations to nonecono-
mists. Some considerations for enhancing presentation formats
are outlined in the following section:1. Presentations of economic evaluations are currently targeted
to technical users. Policymakers have reported challenges
understanding technical concepts such as QALYs and current
graphics such as cost-effectiveness curves [59–61]. Linking
technical concepts to ideas that have practical relevance in a
decision-making context and that are already familiar to
policymakers could be valuable. In addition, ensuring educa-
tional resources and initiatives are in place for policymakers
to gain a better understanding of commonly reported techni-
cal elements is important.2. Policymakers have indicated that disaggregating results
and focusing on the practical relevance of results is important.
Although disaggregation is important, on its own, it may be
insufﬁcient for enhancing policymaker’s understanding.
Following frameworks on how to communicate science
to the lay public could guide audiences toward a better
understanding these technical concepts (e.g., judicious
choice of content, structuring and organizing knowledge,
and use of analogies to explain novel concepts and use of
narratives) [62].3. Even when reporting guidelines are followed, there will
always be complex methodological and modeling decisions
that are open to interpretation and their relevance to
decision-making context should be considered. For example,
limitations in the clinical evidence base and uncertain extrap-
olations of these data frequently inﬂuence the results
of economic evaluations [56–58]. Ensuring these uncertainties
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 9 1 5 – 9 2 4 923and potential limitations are clearly explained to nonecono-
mists is important for enhancing credibility and consistency
in health policy decision making.
Future Research and Conclusions
Knowledge translation approaches have frequently been applied
to enhancing the understandability and accessibility of clinical
trial evidence for policymakers, health care providers, and
patients [63–65]. Some of these initiatives engage policymakers
in developing systematic review or clinical practice guideline
summaries to ensure relevance for stakeholders. However, these
approaches have not been applied in the ﬁeld of health econom-
ics and could be used to develop technically accurate but more
simpliﬁed explanations of economic evaluations for general
audiences. For example, in addition to providing technical reports
and scientiﬁc publications of economic evaluations, decision
support tools could be developed for complex decisions. These
tools could also be used to support educational initiatives or as
supplementary resources for nontechnical audiences. With fur-
ther development of presentation formats that are tailored to
noneconomists, individuals will be able to better apply the results
of economic evaluations to policy decisions and enhance the
transparency and legitimacy of decision-making processes.
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